Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CTMX | US
0.03
2.61%
Healthcare
Biotechnology
30/06/2024
30/08/2024
1.18
1.16
1.18
1.14
CytomX Therapeutics Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009 an antibody drug conjugates (ADC) against CD166 which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer head and neck squamous cell carcinoma esophageal and gastro-esophageal junction cancers and diffuse large B-cell lymphoma; CX-2051 a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801 a dually masked conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288 an anti-CTLA-4 Probody drug which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904 a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company Amgen Inc. Bristol-Myers Squibb Company Astellas Pharma Inc. ModernaTX Inc. and Regeneron Pharmaceuticals Inc. The company was founded in 2008 and is headquartered in South San Francisco California.
View LessStrong P/E, and PEG ratio indicator
Low Debt to Equity (< 0.25)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
42.8%1 month
44.6%3 months
57.6%6 months
318.0%7.87
14.20
5.04
-0.38
0.07
3.86
0.02
-1.80
7.62M
92.18M
92.18M
-
-33.65
-
1.60
-5.48K
12.34
10.15
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.13
Range1M
0.30
Range3M
0.71
Rel. volume
0.35
Price X volume
246.57K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Verastem Inc | VSTM | Biotechnology | 2.5 | 100.61M | 1.63% | n/a | 104.63% |
Verrica Pharmaceuticals Inc | VRCA | Biotechnology | 2.35 | 100.27M | -3.69% | n/a | -348.20% |
IO Biotech Inc. Common Stock | IOBT | Biotechnology | 1.5 | 98.82M | -2.60% | n/a | 2.23% |
Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 2.39 | 97.44M | -0.42% | 4.69 | 0.00% |
VistaGen Therapeutics Inc | VTGN | Biotechnology | 3.49 | 94.42M | -0.85% | n/a | 1.90% |
Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 2.16 | 94.40M | -2.70% | n/a | 35.26% |
InflaRx N.V | IFRX | Biotechnology | 1.59 | 93.62M | -4.22% | n/a | 0.00% |
HilleVax Inc | HLVX | Biotechnology | 1.87 | 93.10M | -1.06% | n/a | 24.92% |
Coya Therapeutics Inc. Common Stock | COYA | Biotechnology | 6.03 | 91.78M | 2.66% | n/a | 0.00% |
I-MAB | IMAB | Biotechnology | 1.13 | 91.40M | 0.89% | n/a | 1.67% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 3.86 | 0.97 | Expensive |
Ent. to Revenue | 0.02 | 3,681.29 | Cheaper |
PE Ratio | 7.87 | 39.83 | Cheaper |
Price to Book | 5.04 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 57.62 | 76.13 | Lower Risk |
Debt to Equity | -0.38 | -2.05 | Expensive |
Debt to Assets | 0.07 | 0.25 | Cheaper |
Market Cap | 92.18M | 4.04B | Emerging |